Laboratory of Experimental Tumor Immunology, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, 3075 EA, The Netherlands.
Trends Mol Med. 2010 Feb;16(2):77-87. doi: 10.1016/j.molmed.2009.12.004. Epub 2010 Feb 1.
T cell receptor (TCR) gene therapy provides patients with autologous T cells that are genetically engineered with TCRalphabeta chains and constitutes a promising approach for the treatment of tumors and virus infections. Among the current challenges of TCR gene therapy is the optimization of TCRalpha and beta transgene pairing to enhance the functional avidity of therapeutic T cells. Recently, various genetically modified TCRs have been developed that enhance TCR pairing and minimize mispairing, i.e. pairing between transgenic and endogenous TCR chains. Here, we classify such receptors according to their CD3-dependence for surface expression and review their abilities to address functional T cell avidity. In addition, we discuss the anticipated clinical value of these and other strategies to generate high-avidity T cells.
T 细胞受体 (TCR) 基因治疗为患者提供了经基因工程改造的自体 T 细胞,这些 T 细胞携带 TCRalphabeta 链,是治疗肿瘤和病毒感染的有前途的方法。目前 TCR 基因治疗面临的挑战之一是优化 TCRalpha 和 beta 转基因配对,以增强治疗性 T 细胞的功能亲和力。最近,已经开发出了各种经过基因修饰的 TCR,这些 TCR 增强了 TCR 配对,减少了错配,即转基因和内源性 TCR 链之间的配对。在这里,我们根据其对表面表达的 CD3 依赖性对这些受体进行分类,并回顾它们解决功能性 T 细胞亲和力的能力。此外,我们还讨论了这些和其他产生高亲和力 T 细胞的策略的预期临床价值。